Eli Lilly and Company $LLY Shares Acquired by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. grew its position in Eli Lilly and Company (NYSE:LLY) by 10.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 143,640 shares of the company’s stock after purchasing an additional 13,561 shares during the period. Eli Lilly and Company comprises about 0.4% of Rakuten Investment Management Inc.’s portfolio, making the stock its 20th largest position. Rakuten Investment Management Inc.’s holdings in Eli Lilly and Company were worth $170,160,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LLY. BlackRock Inc. lifted its holdings in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares in the last quarter. State Street Corp grew its stake in Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after acquiring an additional 605,752 shares during the period. Bank of America Corp DE acquired a new position in Eli Lilly and Company in the second quarter valued at about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after acquiring an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in shares of Eli Lilly and Company by 7.9% in the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after acquiring an additional 400,538 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on LLY shares. HSBC lifted their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. Royal Bank Of Canada increased their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an “outperform” rating in a research note on Friday, October 30th. Wells Fargo & Company increased their target price on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Leerink Partners raised their target price on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a report on Wednesday, October 21st. Finally, Berenberg Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target on the stock in a research note on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,404.14.

Eli Lilly and Company Stock Up 0.6%

LLY stock opened at $1,418.14 on Thursday. The company has a market cap of $1.33 trillion, a price-to-earnings ratio of 46.03, a P/E/G ratio of 1.76 and a beta of 0.40. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,449.68. The business has a 50 day moving average price of $1,207.75 and a two-hundred day moving average price of $1,097.85. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter last year, the company posted $7.02 earnings per share. The company’s revenue for the quarter was up 38.6% compared to the same quarter last year. Analysts anticipate that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A report says Cantor Fitzgerald raised its price target to $1,600 from $1,440 and kept an “overweight” rating, adding to analyst optimism. Cantor Fitzgerald price-target update
• Positive Sentiment: Lilly advanced a next-generation obesity treatment into a Phase 3 study. Further progress could strengthen its pipeline beyond current weight-loss drugs, although the report provides limited trial details. Lilly advances Phase 3 obesity study
• Positive Sentiment: ETFs reportedly bought about $105 million of LLY shares on Nov. 2, suggesting institutional fund demand that may support the stock. ETF purchases of Lilly shares
• Positive Sentiment: In a challenge brought by Lilly, the National Advertising Division recommended that Good Life Meds stop or revise certain claims about compounded tirzepatide products. The recommendation could help Lilly contest marketing by compounded-drug competitors. Advertising claims recommendation
• Neutral Sentiment: EVP Anat Hakim sold 5,000 shares under a pre-arranged Rule 10b5-1 plan. The sale is notable, though the planned nature makes it less clear as a signal about the company’s outlook. Insider sale report
• Negative Sentiment: Recent commentary questions the quality and durability of Lilly’s growth, citing possible one-off revenue benefits and lower realized prices. With expectations and valuation elevated, any deceleration could pressure the shares. Revenue growth quality concerns

Insider Transactions at Eli Lilly and Company

In other news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This trade represents a 54.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 18,500 shares of company stock worth $22,970,770. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.